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Abstract
Background: Incubation period, disease progression, pathology and clinical presentation of classical scrapie in
sheep are highly dependent on PRNP genotype, time and route of inoculation and prion strain. Our experimental
model with pre-colostrum inoculation of homozygous VRQ lambs has shown to be an effective model with
extensive PrPSc dissemination in lymphatic tissue and a short incubation period with severe clinical disease. Serum
protein analysis has shown an elevation of acute phase proteins in the clinical stages of this experimental model,
and here, we investigate changes in gene expression in whole blood, liver and brain.
Results: The animals in the scrapie group showed severe signs of illness 22 weeks post inoculation necessitating
euthanasia at 23 weeks post inoculation. This severe clinical presentation was accompanied by changes in
expression of several genes. The following genes were differentially expressed in whole blood: TLR2, TLR4, C3, IL1B,
LF and SAA, in liver tissue, the following genes differentially expressed: TNF-α, SAA, HP, CP, AAT, TTR and TF, and in
the brain tissue, the following genes were differentially expressed: HP, CP, ALB and TTR.
Conclusions: We report a strong and evident transcriptional innate immune response in the terminal stage of
classical scrapie in these animals. The PRNP genotype and time of inoculation are believed to contribute to the
clinical presentation, including the extensive dissemination of PrPSc throughout the lymphatic tissue.
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Background
Prion diseases are a group of diseases with common path-
ology of the central nervous system including neuronal
degeneration, vacuolation and gliosis [1]. The causative
agent is an infectious protein, called the prion (PrPSc),
which is an abnormal isoform of the cellular prion protein,
PrPC, found in many cell types in the body [2]. Prion dis-
eases are also named Transmissible Spongiform Encephal-
opathies (TSEs), and scrapie is the TSE that affects sheep
and goats. Sheep can become infected early in life, around
and soon after birth, from infectious prions in foetal fluids
and membranes and bodily secretions like colostrum/milk
and faeces [3–6].
Susceptibility to classical scrapie in sheep is highly
dependent on polymorphism at codons 136, 154 and
171 of the PrP gene (PRNP). The five possible alleles,
ARR, AHQ, ARH, ARQ and VRQ, give rise to 15 combi-
nations found in sheep, and these are also linked to the
different presentations of classical scrapie [7]. These ge-
notypes differ widely in their susceptibility to scrapie,
from extreme susceptibility in homozygous V136R154Q171
genotype, to very low susceptibility in homozygous
A136R154R171 [8–10]. The PrP genotype not only influ-
ences the degree of susceptibility, but also the course of
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disease, incubation period and clinical picture [7, 11].
This genetic susceptibility is the basis behind the breed-
ing for resistance program successfully implemented in
the EU as per EC Regulation 999/2001, where only ewes
carrying at least one ARR allele and no VRQ allele, and
rams of ARR/ARR genotype, are bred from [12]. Several
member states have implemented breeding programs to
select for resistance to TSEs in their ovine population,
resulting in a marked increase in ARR frequency and a de-
creased VRQ frequency. There are now reports of a shift
in PRNP genotypes in national flocks after years of breed-
ing from low susceptibility genotypes [13–16]. Thus, the
prevalence of classical scrapie at population level de-
creased as highly susceptible genotypes are eliminated.
Presentation and progression of disease are influenced
by PRNP genotype, PrPSc strain, and route of inocula-
tion. Lateral transmission via the oral route is the most
important and commonest route of infection, and in a
flock where scrapie is endemic, new-born lambs become
infected at birth from their infected dam and/or from
the contaminated environment [17]. After oral infection,
prions seem to be taken up across the gastrointestinal
mucosa by M-cells, and dendritic cells (DCs) and pos-
sibly macrophages are involved in the spread to the
lymphoreticular system (LRS). Follicular dendritic cells
(FDCs) within the LRS, are the site of prion replication,
but the extent and speed of lymphatic involvement is
dependent on PRNP genotype [18]. Sheep carrying the
least susceptible ARR allele show minimal PrPSc depos-
ition within the LRS, while carriers of the VRQ allele are
associated with extensive PrPSc deposition [19–24]. When
lambs with the most susceptible genotype are orally chal-
lenged with scrapie infection, PrPSc is detected very early
in lymphoid tissues associated with the gastrointestinal
tract, and is followed by dissemination of PrPSc to other,
non-gastrointestinal, lymphoid tissues [24–26]. Due to
this early PrPSc accumulation in lymphatic tissue in cer-
tain genotypes, the European Food Safety Authority con-
siders young stock, less than six months of age and from
TSE infected flocks, as potentially highly infectious [27].
The pathogenesis and progression of TSE in different
species is still not fully understood, and sheep with clas-
sical scrapie is a good model to study the disease mecha-
nisms. Pre-colostrum inoculation of lambs at birth is an
effective model that has shown to produce severe clinical
disease after a relatively short incubation period [28].
One can say, our model produces a “worse-case sce-
nario” of prion disease, where the genotype, donor ma-
terial and time of infection are optimal. Ersdal and
co-workers reported a study of PrPSc uptake and dissem-
ination in an earlier experimental model, where older
lambs where orally inoculated, with the same VRQ-prion
donor material, between 46 and 61 days of age [22].
Later, this experimental model was repeated, only this
time the lambs where inoculated at birth, and produced
a much shorter incubation period and more severe clin-
ical disease [28]. Both these models revealed an early
and strong dissemination of PrPSc in lymphatic tissue in
combination with relatively moderate cytopathogenic
changes in the CNS in VRQ/VRQ animals. We have
earlier published our findings of an acute phase response
in lambs inoculated at birth, evident at serum protein
level [29]. In the present study, transcriptional changes
of the above lambs were (further) studied. This article
describes the expression of a selection of genes in RNA
isolated from whole blood, liver and posterior obex of
healthy and scrapie affected lambs.
Many genes are expressed by leukocytes in the blood as
a systemic response to pathology in peripheral tissues. In-
jured and diseased tissues and organs will alter the gene
expression profile in blood leukocytes and in the liver,
which is the main producer of acute phase proteins associ-
ated with an innate immune response. Several studies of
gene expression in circulating blood cells have revealed
expression profiles characteristic for a wide variety of dis-
eases [30–32]. Gene expression studies of whole blood
can thus improve our knowledge of disease related pro-
cesses regardless of which tissue is primarily affected.
White blood cells have an important role in the immune
system, and, although scrapie is known to not produce a
specific immune response per se, cells of the monocyte
line seem to play an important role in the uptake from the
gut and dissemination of PrPSc to lymphoid organs and
further into the CNS resulting in gliosis and astrocytosis
[20, 22].
Collection and stabilization of total RNA from whole
blood using PAXgene Blood RNA Tubes (BD Biosciences)
offer a robust and simple method that minimize
sampling-to-sampling differences. PAXgene technology
capture the RNA profiles at the time of collection of all
cell types in whole blood, including peripheral blood
monocytes, lymphocytes, erythrocytes/reticulocytes, gran-
ulocytes and platelets [33].
The aim of this study was to investigate how scrapie
infection influences the gene expression profile of se-
lected genes in whole blood during the preclinical incu-
bation period and through to the terminal clinical end
stage. Further, the gene expression patterns were studied
in liver and posterior obex at the terminal end stage.
Methods
Animals
The animals and experimental model used in this pro-
ject were described in detail previously, and all animal
procedures were approved by the Norwegian Animal Re-
search Authority [28, 29]. Briefly, nine lambs were inoc-
ulated by stomach tube, at birth and before colostrum
intake, with pooled brain material from either healthy,
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scrapie free sheep (control group) or from confirmed
cases of classical scrapie (scrapie group). All the lambs
originated from the commercial sheep flock belonging to
the Norwegian University of Life Sciences, Faculty of
Veterinary Medicine, Department of Production Animal
Clinical Sciences, Section of Small Ruminant Research,
4325 Sandnes, Norway. Within this flock, a number of
animals have selectively been bred to maintain the
homozygous V136R154Q171 PRNP genotype. The control
group consisted of two twins (four lambs) and the scrapie
group consisted of triplets and twins (five lambs). The
lambs and their dams were housed individually until eu-
thanasia at 23 weeks of age. All the animals were inspected
daily, and the scrapie group was under video surveillance.
Euthanasia was performed by an intravenous injection of
sodium pentobarbital, using the jugular vein.
Blood and tissue collection and RNA isolation
Blood samples were collected at regular intervals from
the jugular vein into appropriate blood tubes, depending
on the requirement for the different analyses. Whole
blood (2.5 mL) was collected at 12, 14, 16, 20, 22 and
23 weeks post inoculation (wpi) in PAXgene Blood RNA
Tubes (Qiagen/BD Company). All the samples were
handled according to manufacturer’s instructions and
stored at minus 70 °C until analysis.
Brain and liver tissues were removed immediately post
mortem and placed in RNAlater (Qiagen) prior to stor-
age at minus 70 °C. Total RNA was extracted and puri-
fied from stabilized blood samples manually, using
PAXgene® Blood miRNA Kit (Qiagen/BD Company) ac-
cording to manufacturer’s instructions using the proto-
col for manual purification. The RNA eluate was
immediately stored at minus70°C.
Total RNA was isolated from 20 to 25 mg tissue sec-
tions, lysed and homogenized, from the posterior obex
region in the brain and from the liver using RNeasy®
Lipid Tissue Midi Kit and (Qiagen) and RNeasy® Lipid
Tissue Mini Kit (Qiagen), respectively, including diges-
tion of DNA using RNase-Free DNase kit (Qiagen).
Total RNA was quantified by UV spectrometry at
260 nm using a NanoDrop ND-1000 spectrophotom-
eter (Saveen and Werner AB, Limhamn, Sweden). In
addition, for each sample 260/280 and 260/230 ratios
were provided, enabling RNA sample purity estima-
tions. RNA integrity was evaluated using the Agilent®
2100 Bioanalyzer with Agilent RNA 6000 Nano Kit
(Agilent Technologies, Waldbronn, Germany), accord-
ing to manufacturer’s instructions. Each total RNA
sample was assigned an RNA Integrity Number (RIN)
ranging from 1 to 10. The mean and standard deviation
of all the RIN values were calculated and are shown in
Additional file 1.
Target genes
Two different primer pairs were designed to amplify dif-
ferent regions of each gene to ensure high quality re-
sults. Sequences used for primer design were obtained
from public database (GenBank, NCBI) and are listed to-
gether with reaction conditions in Additional file 2.
Primers were designed using Primer3 (http://bioinfo.u-
t.ee/primer3-0.4.0/primer3/) and synthesized at TAG
Copenhagen A/S (Copenhagen, Denmark). BLAST
searches were performed to confirm gene specificity of
the primer sequence, and to show the absence of poly-
morphisms at the primer site. Whenever possible, only
sequences from Ovis aries were used, if not, sequences
specific for Bos taurus or Capra ibex were used. Further,
NetPrimer software available at http://www.premierbio-
soft.com was used to obtain a rating value for each pri-
mer pair.
High-throughput qPCR
Two separate technical replicates of complementary
DNA (cDNA) were synthesised from each RNA sample
using 300 ng of total RNA using the QuantiTect
reverse-transcription kit (Qiagen®/BD Company), ac-
cording to the manufacturer’s instructions. All samples
were diluted, with a dilution factor of 0.13, in low
EDTA TE-buffer (VWR, APLIA8569.0500) in a total so-
lution of 20 μl.
Custom-designed primers (TAG Copenhagen,
Copenhagen, Denmark) were diluted to 100 μM. For
preamplification and qPCR, each primer pair, consisting
of forward and reverse primers was further diluted in
low EDTA TE-buffer (VWR, APLIA8569.0500) to reach
a final concentration of 20 μM. Then a primer mix was
created from 5 μl of each 20 μM primer pair and low
EDTA TE-buffer in a 500 μl, 200 nM solution. A Pre-
Amp mix, consisting of 5 μl TaqMan PreAmp Master
Mix (Applied Biosystems, PN 4391128) and 2.5 μl
200 nM primer mix, was added to 2.5 μl of each cDNA
sample. This mix was incubated under thermal cycling
conditions as follows; initially held at 95 °C for 10 min,
followed by 16 pre-amplification cycles of 15 s at 95 °C
and 4 min at 60 °C, before returning to 4 °C. Before
storage at − 20 °C, each sample was diluted 1:4 in low
EDTA TE-buffer. The liver samples were optimised by
a second run, L2; using a 1:10 dilution.
High-throughput qPCR was performed in 48.48 Dy-
namic Arrays using the BioMark thermocycler (Fluidigm
Corporation, CA, USA) following the manufacturer’s
protocol. The 48.48 dynamic array enables 2304 separate
and simultaneous qPCR reactions from 48 samples and
48 primers in one operation. Each 48.48 dynamic array
was prepared with control line fluid and primed in an
IFC Controller MX (Fluidigm Corporation, CA, USA)
while assays and samples were prepared. The Assay
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master mix (2.75 μl), consisted of 2.5 μl loading reagent
(85,000,800 Sample and Assay Loading kit, Fluidigm)
and 0.25 μl low EDTA TE-buffer, were combined with
2.3 μl 20 μM of each specific primer pair before loading
each corresponding assay inlets on the 48.48 dynamic
array. The Pre-sample mix (4.5 μl), consisting of 3 μl
TaqMan Gene Expression Master mix (Applied Biosys-
tems, PN 4369016), 0.3 μl DNA binding dye (100–0388,
Fluidigm), 0.3 μl EvaGreen (VWR, BTIU31000) and
0.9 μl low EDTA TE-buffer, and 1.5 μl preamplified
cDNA sample were added to each corresponding sample
inlets on the 48.48 dynamic array. The 48.48 dynamic
array was then returned to the IFC Controller to load
samples and assays into the Integrated Fluidic Circuit of
the dynamic array. The 48.48 dynamic array was placed in
the BioMark HD instrument for qPCR with a ten-minute
hot start phase at 95 °C followed by 35 cycles of denatur-
ing at 95 °C for 15 s and annealing/elongation at 60 °C for
1 min. Melting curves were generated after each run to
confirm the presence of a single PCR product (from 60 °C
to 95 °C, increasing 1 °C/3 s). Non-template controls,
non-reverse transcriptase controls and three interplate
calibrators were included on each dynamic array if data
from multiple dynamic arrays were analysed.
Data collection and pre-processing
RT-qPCR data was collected using Fluidigm Real-Time
PCR Analysis Software Version 3.0.2 (Fluidigm Corpor-
ation, CA, USA). Melting curves and non-template control
(NTC) were used to monitor non-specific amplification
and sample contamination. Non-reverse transcriptase con-
trols were used to assess potential genomic DNA contam-
ination. Each sample was examined to confirm a single
PCR product, and lack of such product resulted in the re-
jection of that quantification cycle (Cq) value.
Expression data were pre-processed and analysed
using GenEx Pro Version 5.3.6 (MultiD Analyses AB,
Goteborg, Sweden). Pre-processed data were separated
into four data subsets (blood, obex, liver1 and liver2) ac-
cording to type of sample and time of analysis, and data
analysis was performed with GenEx Pro Version 5.3.6 in
the following order: 1. Initial visual evaluation of melting
curves and amplification curves; 2. Efficiency correction.
PCR amplification efficiency was established by the
means of calibration curves and determination of the
slope (S) of the log-linear portion. The calibration curve
was constructed from dilution series (4 × 4) using a pool
consisting of 1 μl of each sample tested, and diluted into
following relative concentrations: F1 0.333, F2 0.067, F3
0.0133 and F4 0.00267. Both slope value (m) and correl-
ation coefficient R2 for each assay was determined using
the above. Efficiency value (E) was calculated as follows:
E = 101/m – 1, and used for the efficiency correction of
each primer assay individually in GenEx. Any assay with
E values less than 0.8 or higher than 1.1, and R2 values
less than 0.95, were discarded and excluded for further
analysis; 3. Inter-plate calibration (IPC): based on the
three interplate calibrators; 4. Normalization to refer-
ence genes. Six different genes (RPLP0, PPIA, UBC,
HPRT1, GAPDH and SDHA) were evaluated using GeN-
orm and NormFinder incorporated in GenEx; 5. Aver-
aging technical cDNA replicates. Before cDNA technical
replicates were averaged, the data set was inspected for
level of variation between replicates. A maximum of
20% of difference in Cq between the two replicates was
accepted.; 6. The relative expression of each sample ana-
lysed, was calculated using the mean Cq value of the
control croup as a base line. Any sample with higher Cq
(lower expression) than mean Cq of control group, get a
value below 1, and any sample with lower Cq (higher ex-
pression) than mean Cq of control group, get a value
above 1. This was done for each primer assay individu-
ally; 7. Finally, the data was converted into logarithmic
scale, using log2 transformation for all statistical analysis.
Fold change was calculated by scaling the relative ex-
pression data. A scaling factor was calculated based on
the average relative expression (fold change) in the con-
trol group was scaled to 1. Individual expression data
was multiplied by the scaling factor, giving individual
fold change. Average fold change and standard error of
the mean (SEM) was calculated for each group/primer
assay. When relative expression (RE) was below 1, it was
translated to a negative fold change value using −
2-(log2
RE), i.e. a relative expression of 0.8, gave a fold
change of − 1.2.
Statistical analysis
The data were analysed separately using statistical features
of GenEx software (MultiD). The pre-processed data from
the qPCR analyses was separated into subsets of data,
based on time and type of sampling. The non-parametric
statistical model, Mann-Whitney U Test, was used to cal-
culate p-values between scrapie and control groups in
each of the data subsets, and significant p-value was set to
p < 0.05. Due to the small group size, p-values should be
interpreted with some caution. Genes were considered as
differentially expressed if they showed a fold change of
≥1.5 and reached significant p-values.
Results
Animals
Animals in the control group remained healthy without
any clinical symptoms for the full experimental period. No
obvious clinical signs of illness were visible in the scrapie
group until 22 wpi, although subtle signs of unspecific
ill-thrift were observed in two animals from 19 wpi. By
the end of 22 wpi., all the animals in the scrapie group
showed signs of disease, such as weakness, dullness and
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lethargy. Two animals in the infected group displayed an
accelerated worsening of clinical signs to terminal recum-
bency and severe depression. This sudden change, over a
few days, made euthanasia necessary. Brain tissue from all
the animals in both groups was examined for PrPSc by im-
munohistochemistry (IHC) and Western Blot (WB), and
only the animals in the scrapie group were found
PrPSc-positive (Fig. 1). There were moderate vacuolation
of neuropil and neurons with marked distribution of PrPSc
deposits in the CNS, and PrPSc was found to be widely
distributed in lymphoid organs (spleen and retropharyn-
geal lymph nodes), consistent with previous findings [28].
Gene expression analysis in blood
Statistically differentially expressed genes, fold change
and p-value are summarized in Table 1. The magnitude
of the fold change at each time points, reflects the gene
expression alterations relative to the mean level of the
control group scaled to 1. Of the 10 target genes ana-
lysed after pre-processing, only six were significantly dif-
ferently expressed in the scrapie group compared to the
control group at any time point. No genes were differen-
tially expressed at 12 nor 14 wpi. IL1B was differentially
expressed at 16 and 22 wpi, and TLR2, TLR4, C3 and
SAA were differentially expressed at 22 and 23 wpi. LF
was only differentially expressed at 23 wpi. Apart from
IL-1B which was downregulated at 16 wpi, all the others
were upregulated. Expression levels of TLR9, IL1RN, IL8
and LR/LAMR1 were not significantly altered at any of
the time points. (Table 1).
Gene expression analysis in liver at 23 wpi
Due to the small group size, only descriptive analyses
were performed. Differentially expressed genes of the
scrapie group relative to the control group with a fold
change of ≥1.5 can be seen in Table 2. The fold change
value is relative to the mean expression level in the con-
trol group, set as value 1. Of the 12 target genes analysed
after pre-processing, seven genes were expressed with
fold change ≥1.5 (Table 2). Three genes were upregu-
lated (SAA, Hp and Cp) and four were downregulated
(TNFa, AAT, TF and TTR).
Gene expression analysis in brain at 23 wpi
Gene expression differences in brain tissue are listed in
Table 3. Out of 12 target genes analysed after
pre-processing, only four were expressed with fold
change ≥1.5. Hp and Cp were upregulated, and ALB and
TTR were downregulated.
Discussion
Classical scrapie is known to present with a variety of clin-
ical signs, and clinical presentation is dependent on PRNP
genotype, PrPSc strain, infective dose and age of host at in-
fection. Our experimental model resembles natural infec-
tion and illustrates the “worst-case” scenario which can
occur naturally when the right conditions are present.
Clinical signs of disease in the scrapie group was first ob-
served at 19 wpi. The symptoms aggravated quickly, and
by 23 wpi, two lambs had reached the terminal stages.
The very short incubation period was dominated by
Fig. 1 Western Blot image. Western immunoblot using P4 antibody for the detection of PrPSc in equal amount of homogenated brain tissue
from animals and inoculation material used in the experiment (TeSeE Western Blot, Bio-Rad). Lanes 1–5 represent the five animals in the scrapie
group, and lanes 6 and 7 represent two animals in the control group. Lane 8 represents inoculation material (donor) used in the scrapie group
and a molecular marker was placed in lane 9. PrPSc was detected in inoculation material and in all the animals from the scrapie group
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sudden progressive weakness, followed by rapid worsening
and necessitating euthanasia at an early age. Hence, the
observed clinical presentation is not typical for classical
scrapie known to present in older animals, which is char-
acterised by a slow and long incubation period with signs
of progressive neurodegeneration associated with dissem-
ination and accumulation of PrPSc within the CNS. Al-
though this experimental scrapie model attempts to
eliminate many of the factors that generate disease vari-
ation, individual variation still occurred. Individual pro-
gression of clinical disease and expression profiles in
blood and tissues differs between animals. The APR is fast,
and the level of inflammatory mediators, such as cyto-
kines, changes continuously. Cytokines are multifunc-
tional (both pro-inflammatory and anti-inflammatory)
intra-cellular and inter-cellular signalling molecules, oper-
ating in a very complex signalling network to initiate and
fine-tune the immune response [34–38]. Their levels are
tightly controlled within a narrow range by inhibitory
mechanisms and antagonists, whilst APPs can increase
quite dramatically depending on type of protein [39, 40].
In the present study, we have investigated the expression
of a selection of genes in blood approximately half-way
through the incubation period, at 12–16 wpi, and at the
clinical end-stage, at 22–23 wpi. Expression levels of se-
lected genes were also investigated in liver and brain tis-
sues, harvested at post mortem examination. In summary,
the mean expression of six genes were significantly altered
in the scrapie group compared to the control group. We
were not able to calculate statistical significance in mean
expression levels in brain and liver tissues, but we believe
that a difference in mean expression levels greater than
1.5 fold change is of biological relevance and will be dis-
cussed. Despite our best efforts, only four genes in the
brain tissue were differently expressed in the scrapie
group, compared to the control group. These findings
were unexpected as all the animals in the scrapie group
were clinically affected and were positive for PrPSc in the
brain on both IHC examination and WB (Fig. 1).
Our overall results, presented in Fig. 2, indicate an in-
nate immune response, where genes involved in pattern
recognition, complement system and acute phase pro-
teins, are significantly altered in blood at the clinical
stages (22 and 23 wpi). Mean gene expression levels of
brain and liver tissues in the scrapie group show ≥1.5
fold change of several APPs. These findings coincide
well with our earlier reports on increased serum levels
of APPs, and identification of SAA as being a discrimin-
ating protein by proteomic analysis of serum from the
scrapie group [29, 41].
Prion disease and the innate immune system have pre-
viously been reviewed by Bradford and Mabbott, and ac-
tivation of cells within the innate immune system is
critical to peripheral and central prion pathogenesis [42].
Table 1 Mean fold change and p-values of selected genes in whole blood at three time points
Gene function Gene name Whole blood
16 wpi 22 wpi 23 wpi
FC ± SEM p FC ± SEM p FC ± SEM p
Pattern Recognition Receptor TLR2 Toll-like receptor 2 1.11 ± 0.04 0.73 1.96 ± 0.28 0.02 1.98 ± 0.54 0.03
TLR4 Toll-like receptor 4 −1.41 ± 0.05 0.41 2.14 ± 0.42 0.02 2.00 ± 0.42 0.03
Complement Component C3 Complement
component 3
1.57 ± 0.22 0.19 3.04 ± 0.91 0.02 4.74 ± 2.32 0.02
Interleukin IL1B Interleukin-1β −1.71 ± 0.03 0.02 1.66 ± 0.16 0.02 −1.24 ± 0.15 > 0.05
Acute Phase Protein SAA Serum Amyloid A 1.07 ± 0.35 0.73 5.00 ± 1.49 0.02 21.99 ± 18.03 0.03
LF Lactoferrin 1.05 ± 0.35 1.00 4.64 ± 2.64 0.06 13.70 ± 10.35 0.02
Mean fold change (FC) with standard error of the mean (SEM) and p-value of differentially expressed genes in whole blood in the scrapie group. The mean fold
change value is relative to the mean of the control group which is scaled to 1, at each of the different times (weeks) post inoculation
Table 2 Fold change of selected genes in liver tissue
Gene function Gene Name Fold change ± SEM
TNF super family TNFa Tumor Necrosis Factor alfa −1.77 ± 0.12
Acute phase protein SAA Serum Amyloid A 89.98 ± 46.32
TF Transferrin −1.68 ± 0.10
Hp Haptoglobin 542.96 ± 216.93
Cp Ceruloplasmin 1.98 ± 0.46
AAT Alpha-1 antitrypsin −2.37 ± 0.05
TTR Transthyretin −2.03 ± 0.08
Mean hepatic gene expression and SEM of the scrapie group at 23 wpi with fold change ≥1.5 relative to the mean expression in the control group scaled to 1
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Gene network analyses of brain tissue from prion in-
fected mice show that increased expression of C3, PRRs
(including TLR2), and other receptors involved with
PrPSc recognition and uptake are one of the first tran-
scriptome changes [43, 44]. TLR2 is one of the, at least,
ten members of the ovine TLRs family which are
membrane-bound PRRs [45]. Our results show signifi-
cantly increased TLR2 and TLR4 expression in blood
from 22 wpi, thus, indicating an increased transcription
of these receptors in circulating blood cells. Both these
TLRs are situated on the cell surface and recognize a
variety of microbial components, and activation will trig-
ger expression of several genes and signalling pathways
involved in the immune response [37, 46, 47]. Activation
of different TLRs leads to specific gene expression pro-
file patterns, and the specific signalling pathways in
prion diseases are not yet fully revealed. TLR2 and TLR4
signalling pathways share a common MyD88-dependent
pathway which results in production of inflammatory cy-
tokines. In addition, TLR4 stimulation can also initiate a
MyD88-independent pathway [46]. Prinz et al. demon-
strated that MyD88−/− mice were highly susceptible to
prion infection, and thus pathogenesis and neuroinvasion
are not solely dependent on the MyD88-dependent path-
way [48]. Spinner et al. showed that scrapie pathogenesis
occurs more rapidly in mice mutant of TLR4 signalling and
concludes that this may be due to a reduced innate
response to PrPSc [49]. The TLRs may be involved in
binding PrPSc and initiating the innate immune response
[42, 48–52]. Alongside the TLRs, there is a significant
increased expression of C3 in blood at both 22 and 23
wpi. Binding of PrPSc to complement components plays
an important role in getting the agent to lymphoid tis-
sue and early accumulation in FDCs [53]. PrPSc inter-
acts directly with C1q and thereby activates C3 through
the classical pathway [54–56]. The complement system,
in general, sense and react quickly to danger signals
and can potentially initiate a strong inflammatory re-
sponse, which needs to be tightly balanced between ac-
tivation and inhibition [54].
Binding to and activation of PRRs lead to the production
of pro-inflammatory cytokines that function both protect-
ive and degenerative. Increased levels of pro-inflammatory
cytokines are associated with the systemic inflammatory
response seen in prion infection and other neurodegener-
ative diseases [57, 58]. Cytokine antibody array analysis of
scrapie-infected Tg338 mice shows significant alteration
in expression of interleukins in spleen, mesenteric lymph
node, brain and serum at both preclinical and clinical
stages of infection [59]. We analysed several different in-
terleukins, but only the expression IL1B was significantly
changed in blood in the scrapie group; first downregulated
at 16 wpi and then upregulated at 22 wpi. IL-1 beta is a
powerful pro inflammatory mediator, and increased levels
initiate a negative feedback loop [35, 39].
Translation and release of proinflammatory cytokines
initiate a wide range of systemic inflammatory effects,
including the synthesis and release of APPs mainly from
the liver, but also extrahepatically [36, 38, 47, 60]. The
APPs are classified as positive or negative depending
Table 3 Fold change of selected genes in brain tissue
Gene function Gene Name Fold Change ± SEM
Acute Phase Protein Hp Haptoglobin 7.91 ± 2.39
Cp Ceruloplasmin 1.67 ± 0.73
ALB Albumin −1.64 ± 0.06
TTR Transthyretrin −1.61 ± 0.17
Mean fold change and SEM in brain tissue in the scrapie infected group at 23
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whether their serum concentration increases or de-
creases during the APR [36, 47, 61, 62]. Our results
show changes at transcription levels of both negative
and positive APPs at the end stage. ALB, TTR and TF
are negative APPs, and these have decreased expression
in brain and liver. ALB is the major negative APP and
synthesis is down-regulated during the APR. Transthyre-
tin is a transport protein in serum and CSF, and one of
its functions is inhibition of interleukin-1 production by
monocytes and endothelial cells, and a decrease may,
thus be pro-inflammatory [36]. TTR expression is re-
duced during the APR and the protein has been seen to
decrease in serum in late stage scrapie in sheep [63, 64].
Of the positive APPs, LF, Cp, SAA and Hp have in-
creased expression at clinical end stage, while AAT was
down regulated. Alpha-1 antitrypsin (AAT) is a circulat-
ing serine protease inhibitor (serpin) and an acute phase
protease, and it is classified as a minor positive acute
phase protein in ruminants [64]. It is synthesised and se-
creted from the liver, and it plays an important role in
the control of the inflammatory response [47, 65]. Serpi-
nopathies and AAT deficiency have been associated with
protein misfolding diseases [65, 66]. We found a de-
creased transcription of AAT mRNA in the liver in the
scrapie group compared to the control group.
Gene expression of lactoferrin (LF), another minor
positive APP, was increased by a 13.7-fold in blood in
the scrapie group at 23 wpi. LF is a multifunctional
glycoprotein with great iron-binding affinity and it is
produced by mucosal epithelial cells [67]. It is involved
in regulation of iron absorption and immune responses,
and it has been suggested that LF has multifunctional
antiprion activities [68]. Neutrophils are the source of
lactoferrin in serum [69].
Ceruloplasmin (Cp) is a moderate APP with important
biological functions. It is the major copper-carrying pro-
tein in blood, it plays a role in iron homeostasis and has
oxidase activity in the CNS [47, 70–72]. Cp is mainly
produced in the liver, and we detected an increased tran-
scription in liver tissue in the scrapie group at 23 wpi.
This coincides well with our previous finding of in-
creased serum levels of ceruloplasmin at 23 wpi [29].
Serum amyloid A (SAA) and haptoglobin (Hp) are
major APPs in sheep and increased serum levels are as-
sociated with a number of diseases. These proteins are
primarily synthesised by hepatocytes, but other tissues
and cell types are able to produce these two locally,
though at a much lower level [47]. Our results show an
increased transcription of both genes in the scrapie
group at the clinical end stage. SAA gene expression in
blood was significantly increased at both 22 and 23 wpi,
with an average fold change of 5.00 and 21.99, respect-
ively. In liver tissue, the mean expression level was in-
creased by an average 89.98 fold change in the scrapie
group. These results indicate that the increased level of
SAA in in serum, reported earlier, originates both from
increased synthesis in the liver and in the blood.
Hp showed increased gene transcription in both liver
and brain tissue, with a mean fold change of 542.86 and
7.91, respectively. This indicates an increased synthesis
of Hp hepatically and extrahepatically within the brain
in the scrapie group at 23 wpi.
There was considerable variation in relative expression
of individual gene expression within the scrapie group,
indicated by the SEM values (Tables 1-3). One animal
stands out in gene expression fold change in liver and
blood, and on clinical presentation (individual data not
shown). We believe there is relationship between the
magnitude of the systemic acute phase response and
clinical presentation in these animals. The acute phase
response leads to a number of behavioural, physiological,
biochemical and nutritional changes [36]. The brain rec-
ognizes proinflammatory cytokines as molecular signals
of sickness, and metabolic and behavioural changes are
initiated. These changes are collectively called “sickness
behaviour” [73]. These peripherally released cytokines
communicate and act on the brain via a fast neural path-
way through afferent neurons (especially the vagus nerve),
and via a slow humoral pathway [37]. In this sense, the
immune- and nervous systems are in close contact. The
afferent branches of the vagus nerve are involved in trans-
mitting signals of inflammation to the brain via cytokine
receptors [37]. Dendritic cells and macrophages are
present in close association to vagal nerve fibres and they
are important in the immune-brain communication [74].
Dendritic cells and macrophages express membrane TLRs
and can produce proinflammatory cytokines upon activa-
tion, and at the same time, these cell types play a role in
peripheral prion pathogenesis by interacting with PrPSc
[42, 75]. Immune signals and PrPSc neuroinvasion may
share common neural pathway transmitting immune mes-
sages and PrPSc infectivity, respectively, from periphery to
the brain, where DCs have an important role [37, 76]. The
innate immune system and the nervous system are, thus
closely linked through common hormonal and neuronal
routes. The ANS and CNS enhance and dampen the in-
flammatory response, and regulation through negative
feedback loops are important. Any interference may have
deleterious consequences. Recently, Salvesen et al. sug-
gested that PrPC is one of the modulators of the innate
immune response, and loss of PrPC prolonged sickness be-
haviour and stimulated pro-inflammatory activity [77].
Similar experimental scrapie models in sheep show
PrPSc accumulation in peripheral lymphatic tissue and
gene expression changes about half-way through the in-
cubation period, while the animals appear asymptomatic
[20, 22, 24, 43]. We believe the situation in the scrapie
group was similar, an asymptomatic incubation period
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was followed be a short clinical end stage characterised
by progressive apathy, dirty wool and passiveness. By 23
wpi two sheep were recumbent, weak, incapacitated and
responded poorly to external stimuli. Sheep are very
good at hiding behaviour changes as indicators of dis-
ease, thus presence of clinical signs cannot always be re-
lied upon [78]. Sickness behaviour can be both beneficial
and disadvantageous to the animal, and it can, to some
extent, be overruled by fear and mothering behaviour
[73, 79]. Why the long asymptomatic incubation period,
despite the ongoing accumulation of PrPSc in LRS and
CNS and gene expressions alterations, is not fully under-
stood. Many of the genes involved are part of the innate
immune system, and it is known that a prolonged and
excessive inflammatory response can have negative or
even lethal effects [34, 37, 80].
The particular disease phenotype seen in present
study, is the result of the interaction between donor ma-
terial, dosage and time of inoculation and recipient
genotype, also described by González et al. [81]. The in-
oculation at birth before access to colostrum results in
an effective and fast uptake of PrPSc across the suscep-
tible new-born gut, similarly described by Tabouret et al.
[24, 28]. These lambs have a characteristic dissemination
of PrPSc throughout peripheral lymphatic tissues well in
advance of PrPSc detection in the brain. The early and
progressive development of clinical signs is unusual and
have only been described earlier in a few rare cases of
natural scrapie by Ulvund, although not at such a young
age [82]. The histopathological examinations of the brain
from these pre-colostrum inoculated lambs revealed only
moderate cytopathological changes, with a mild to mod-
erate gliosis with few vacuolated neurons. This is in
somewhat in contrast to an earlier experimental model,
described by Ersdal et al., where lambs of the same
genotype (VRQ) were orally inoculated with brain tissue
homogenate at ages between 46 and 61 days of age
(mean 55.6 days).
Conclusion
We believe our experimental model produces a “worst--
case” scenario which can occur in natural scrapie settings.
Homozygous VRQ offspring from subclinically infected
ewes, can become infected at birth and develop clinical
scrapie similar to the cases described here. In naturally oc-
curring scrapie, such animals will pose a threat to other
susceptible sheep through environmental contamination
due to high infectivity. The young age and atypical clinical
presentation of these cases can result in misdiagnosis and
not be recognisable as scrapie. Further work is needed to
investigate the connection between the innate immune
system and prion diseases, and whether the severe re-
sponse we observed in our model can be linked to loss of
modulatory function of PrPC.
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